Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Nuvation Bio 週六披露了他們實驗性的 ROS1 抑制劑 Taletrectinib 在 ASCO 2024 的關鍵二期 TRUST-I 臨牀試驗中的發現。
- Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
- Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
- TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC
- 在進行研究的未接受ROS1酪氨酸激酶抑制劑（TKI）的進展期ROS1陽性非小細胞肺癌患者中，91%的人使用愛文思控股治療後腫瘤萎縮，而在先前接受ROS1 TKI治療的患者中佔52%。
- 持久的治療效果得到長期隨訪的證實；71%的未接受TKI治療的患者在兩年後仍沒有進展。
- TRUST-I是進行註冊的兩個II期研究，評估taletrectinib用於治療進展期ROS1陽性非小細胞肺癌患者之一。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。